Free Trial
→ Read now. Do not delete. You’ve been warned. (From Porter & Company) (Ad)tc pixel Free TPST Stock Alerts

Tempest Therapeutics (TPST) Competitors

Tempest Therapeutics logo
$1.27 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$1.30 +0.03 (+2.36%)
As of 06:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

TPST vs. FRMM, CTOR, GANX, XBIT, and PLRX

Should you buy Tempest Therapeutics stock or one of its competitors? MarketBeat compares Tempest Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tempest Therapeutics include Forum Markets (FRMM), Citius Oncology (CTOR), Gain Therapeutics (GANX), XBiotech (XBIT), and Pliant Therapeutics (PLRX). These companies are all part of the "pharmaceutical products" industry.

How does Tempest Therapeutics compare to Forum Markets?

Tempest Therapeutics (NASDAQ:TPST) and Forum Markets (NASDAQ:FRMM) are both small-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, dividends, earnings, valuation, institutional ownership, profitability, analyst recommendations and media sentiment.

22.5% of Tempest Therapeutics shares are owned by institutional investors. Comparatively, 4.1% of Forum Markets shares are owned by institutional investors. 6.3% of Tempest Therapeutics shares are owned by company insiders. Comparatively, 15.1% of Forum Markets shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Forum Markets' return on equity of -242.09% beat Tempest Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Tempest TherapeuticsN/A -355.61% -121.21%
Forum Markets N/A -242.09%-135.46%

Tempest Therapeutics has a beta of -1.85, meaning that its stock price is 285% less volatile than the broader market. Comparatively, Forum Markets has a beta of 1.45, meaning that its stock price is 45% more volatile than the broader market.

In the previous week, Tempest Therapeutics had 2 more articles in the media than Forum Markets. MarketBeat recorded 3 mentions for Tempest Therapeutics and 1 mentions for Forum Markets. Forum Markets' average media sentiment score of 1.89 beat Tempest Therapeutics' score of 1.28 indicating that Forum Markets is being referred to more favorably in the news media.

Company Overall Sentiment
Tempest Therapeutics Positive
Forum Markets Very Positive

Forum Markets has a consensus price target of $10.00, suggesting a potential upside of 80.83%. Given Forum Markets' stronger consensus rating and higher probable upside, analysts clearly believe Forum Markets is more favorable than Tempest Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Tempest Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50
Forum Markets
1 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.50

Tempest Therapeutics has higher earnings, but lower revenue than Forum Markets. Tempest Therapeutics is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Tempest TherapeuticsN/AN/A-$26.26M-$6.01N/A
Forum Markets$6.55M12.28-$450.52M-$36.07N/A

Summary

Forum Markets beats Tempest Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Tempest Therapeutics compare to Citius Oncology?

Citius Oncology (NASDAQ:CTOR) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation.

In the previous week, Tempest Therapeutics had 1 more articles in the media than Citius Oncology. MarketBeat recorded 3 mentions for Tempest Therapeutics and 2 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 1.32 beat Tempest Therapeutics' score of 1.28 indicating that Citius Oncology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Citius Oncology
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tempest Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Citius Oncology has a beta of 3.41, meaning that its stock price is 241% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.85, meaning that its stock price is 285% less volatile than the broader market.

Citius Oncology presently has a consensus target price of $6.00, suggesting a potential upside of 773.62%. Given Citius Oncology's stronger consensus rating and higher probable upside, equities analysts plainly believe Citius Oncology is more favorable than Tempest Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Citius Oncology
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33
Tempest Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Citius Oncology is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Citius OncologyN/AN/A-$24.76M-$0.47N/A
Tempest TherapeuticsN/AN/A-$26.26M-$6.01N/A

70.5% of Citius Oncology shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 9.8% of Citius Oncology shares are held by company insiders. Comparatively, 6.3% of Tempest Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Citius Oncology's return on equity of -99.47% beat Tempest Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Citius OncologyN/A -99.47% -42.16%
Tempest Therapeutics N/A -355.61%-121.21%

Summary

Citius Oncology beats Tempest Therapeutics on 11 of the 12 factors compared between the two stocks.

How does Tempest Therapeutics compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, valuation, earnings, analyst recommendations, profitability, risk and dividends.

Gain Therapeutics' return on equity of -201.44% beat Tempest Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gain TherapeuticsN/A -201.44% -136.24%
Tempest Therapeutics N/A -355.61%-121.21%

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 4.2% of Gain Therapeutics shares are held by insiders. Comparatively, 6.3% of Tempest Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Gain Therapeutics presently has a consensus price target of $8.50, suggesting a potential upside of 418.29%. Given Gain Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Gain Therapeutics is more favorable than Tempest Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gain Therapeutics
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67
Tempest Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

In the previous week, Gain Therapeutics had 1 more articles in the media than Tempest Therapeutics. MarketBeat recorded 4 mentions for Gain Therapeutics and 3 mentions for Tempest Therapeutics. Tempest Therapeutics' average media sentiment score of 1.28 beat Gain Therapeutics' score of 0.63 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gain Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tempest Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Gain Therapeutics has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.85, meaning that its stock price is 285% less volatile than the broader market.

Gain Therapeutics has higher revenue and earnings than Tempest Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gain Therapeutics$50K1,398.92-$20.16M-$0.58N/A
Tempest TherapeuticsN/AN/A-$26.26M-$6.01N/A

Summary

Gain Therapeutics beats Tempest Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Tempest Therapeutics compare to XBiotech?

XBiotech (NASDAQ:XBIT) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are owned by institutional investors. 30.8% of XBiotech shares are owned by company insiders. Comparatively, 6.3% of Tempest Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

XBiotech has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.85, meaning that its stock price is 285% less volatile than the broader market.

XBiotech is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
XBiotechN/AN/A-$45.54M-$1.32N/A
Tempest TherapeuticsN/AN/A-$26.26M-$6.01N/A

XBiotech's return on equity of -26.10% beat Tempest Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
XBiotechN/A -26.10% -25.06%
Tempest Therapeutics N/A -355.61%-121.21%

In the previous week, Tempest Therapeutics had 2 more articles in the media than XBiotech. MarketBeat recorded 3 mentions for Tempest Therapeutics and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.87 beat Tempest Therapeutics' score of 1.28 indicating that XBiotech is being referred to more favorably in the media.

Company Overall Sentiment
XBiotech Very Positive
Tempest Therapeutics Positive

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
XBiotech
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Tempest Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Summary

XBiotech beats Tempest Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Tempest Therapeutics compare to Pliant Therapeutics?

Pliant Therapeutics (NASDAQ:PLRX) and Tempest Therapeutics (NASDAQ:TPST) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, dividends, risk, valuation, analyst recommendations, institutional ownership and media sentiment.

Tempest Therapeutics has lower revenue, but higher earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Tempest Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pliant Therapeutics$1.58M45.46-$149.34M-$1.84N/A
Tempest TherapeuticsN/AN/A-$26.26M-$6.01N/A

Pliant Therapeutics has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Tempest Therapeutics has a beta of -1.85, meaning that its stock price is 285% less volatile than the broader market.

Pliant Therapeutics presently has a consensus target price of $3.00, suggesting a potential upside of 158.62%. Given Pliant Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pliant Therapeutics is more favorable than Tempest Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pliant Therapeutics
2 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.80
Tempest Therapeutics
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

97.3% of Pliant Therapeutics shares are held by institutional investors. Comparatively, 22.5% of Tempest Therapeutics shares are held by institutional investors. 8.0% of Pliant Therapeutics shares are held by company insiders. Comparatively, 6.3% of Tempest Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Pliant Therapeutics' return on equity of -58.11% beat Tempest Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Pliant TherapeuticsN/A -58.11% -44.37%
Tempest Therapeutics N/A -355.61%-121.21%

In the previous week, Tempest Therapeutics had 1 more articles in the media than Pliant Therapeutics. MarketBeat recorded 3 mentions for Tempest Therapeutics and 2 mentions for Pliant Therapeutics. Tempest Therapeutics' average media sentiment score of 1.28 beat Pliant Therapeutics' score of 0.93 indicating that Tempest Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pliant Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Tempest Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Pliant Therapeutics beats Tempest Therapeutics on 10 of the 13 factors compared between the two stocks.

Get Tempest Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for TPST and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TPST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TPST vs. The Competition

Export
MetricTempest TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$18.81M$2.94B$6.41B$11.71B
Dividend YieldN/A1.71%2.67%5.55%
P/E RatioN/A17.8024.4623.62
Price / SalesN/A289.23500.50105.26
Price / CashN/A55.7442.3656.09
Price / Book0.943.8810.436.70
Net Income-$26.26M$75.85M$3.56B$337.26M
7 Day PerformanceN/A-1.87%-1.39%-1.41%
1 Month Performance-36.18%-6.20%0.86%1.15%
1 Year Performance-85.70%12.60%19.42%22.61%

Tempest Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TPST
Tempest Therapeutics
2.6977 of 5 stars		$1.27
flat		N/A-85.8%$18.81MN/AN/A20
FRMM
Forum Markets
2.9158 of 5 stars		$5.31
+4.3%		$10.00
+88.3%		N/A$74.02M$6.55MN/A7
CTOR
Citius Oncology
1.8835 of 5 stars		$0.80
+2.6%		$6.00
+650.1%		-41.5%$72.53MN/AN/AN/A
GANX
Gain Therapeutics
2.368 of 5 stars		$1.69
-0.6%		$8.50
+403.0%		-13.6%$72.51M$50KN/A20
XBIT
XBiotech
1.0478 of 5 stars		$2.37
flat		N/A-19.4%$72.26MN/AN/A100

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:TPST) was last updated on 6/10/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Live demo of Elon Musk’s AI agent
Jeff Brown picked Nvidia in 2016 - it's up 25,155%. He recommended Bitcoin at $240 - it's up 31,219%. Now he's...
Brownstone Research | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
No. You’re not imagining it…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Important SpaceX PREDICTION from Trading Legend Jon Najarian
Trading legend Jon Najarian says the real story behind the projected June 12 SpaceX IPO isn't the IPO itself -...
Banyan Hill Publishing | Sponsoredtc pixel